Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma. (2018). SKIN The Journal of Cutaneous Medicine, 2, S79. https://doi.org/10.25251/skin.2.supp.79